Ramucirumab and durvalumab for previously treated, advanced non–small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma
Combining Cyramza with IMFINZI® (durvalumab) was safe and effective in a small trial that included gastric cancer patients.
